Madrigal Pharmaceuticals Inc

Change company Symbol lookup

Select an option...

MDGL Madrigal Pharmaceuticals Inc

BKE Buckle Inc

ROP Roper Technologies Inc

ESYJY Easyjet PLC

OGE OGE Energy Corp

ASB-E Associated Banc-Corp

LI Li Auto Inc

IKT Inhibikase Therapeutics Inc

GSIT GSI Technology Inc

AZRE Azure Power Global Ltd

Go

Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a proprietary, liver-directed, selective thyroid hormone receptor-B (THR-B), agonist being developed as a once-daily oral pill for the treatment of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). NASH is a liver disease that affects people with metabolic diseases, such as obesity and diabetes and non-alcoholic fatty liver disease (NAFLD).